David Morrow (EATRIS Senior Scientific Program Manager) was in Bulgaria this month to present at a workshop about the Bulgarian national infrastructure capacity In Translation Medicine. His talk was entitled: “EATRIS ATMP and VIIM Platforms and the new landscape of translational medicine”.
The workshop took place on 5 November 2022 in the Sheraton Sofia Hotel Balkan under the patronage of the National Infrastructure “Cell Technologies in Biomedicine” of the National Roadmap of Research Infrastructures of Bulgaria and was organised by the EATRIS Bulgaria Node. The event aimed to reinforce the interest of the scientific community around topics of personalised medicine, the latest developments in the area of induced pluripotent stem cells, challenges and perspectives for translation of this research, with a focus on national developments.
David presented before the audience consisting of academics from national research institutes and medical universities, but also of different other stakeholders from the public and private sector the latest developments in the ATMP Platform and current initiatives in support of the development of next-generation cell and gene therapies. He focused his talk on the ISIDORe project to support researchers in the development of therapies and vaccines for infectious diseases, as well as on the new canSERV project supporting the development of therapies against cancer. Great interest was shown by Bulgarian researchers to apply for services offered by the projects. The session was moderated by EATRIS National Director Prof. Rossitza Konakchieva from Sofia University. EATRIS National Coordinator Assoc. Prof. Georgi Georgiev from the Faculty of Biology, Sofia University, presented the EATRIS-Plus project activities and development.
During the session the new COST action CA21151 “HAPLO-iPS: GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELLS FROM HAPLO-SELECTED CORD BLOOD SAMPLES” was presented by Begoña Aran, PhD and Ester Rodriguez, PhD from IDIBELL (Bellvitge Biomedical Research Institute) and P-CMR[C] (Program for Clinical Translation of Regenerative Medicine in Catalonia). Opportunities for national collaborations and perspectives on new partnerships were discussed.